Project Grant R16DA062584
Award Date
8/15/24
Completion Date
6/30/28
Dollars Obligated
$318K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award of $1,749,120.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to study the "Incubation of Oxycodone Craving and Nucleus Accumbens Plasticity." The research aims to investigate the persistence of vulnerability to cue-induced relapse in opioid addiction, specifically for the opioid oxycodone, even after long periods of abstinence. The project will use the "incubation...
This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,188,822 to the Icahn School of Medicine at Mount Sinai to conduct research on the molecular and cellular mechanisms underlying opioid tolerance and withdrawal. The research project aims to profile gene expression and neuronal activity in the habenula-interpeduncular nucleus circuit in response to chronic oxycodone exposure in male and...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This Project Grant award of $1,539,260 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to study the role of the kappa opioid receptor (KOR) system in opioid use disorder (OUD). The key objectives are to: Use PET imaging to compare KOR availability in early abstinent individuals with moderate-to-severe OUD (N=40) versus healthy controls (N=30). Examine the clinical and transdiagnostic relevance of KOR,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to explore the unique neurobehavioral profile of sequential opioid-stimulant polysubstance use disorders. The $314,225 award, effective July 31, 2024 through February 28, 2025, will fund a study conducted by the University of Washington to: 1) Define the behavioral profile of dual opioid-methamphetamine use disorders in a...
This $284,040 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to conduct integrated single-cell and spatial mapping of the habenula circuitry to identify projection-specific molecular pathways associated with opioid exposure. The Lieber Institute for Brain Development in Baltimore, MD will lead this research effort from September 1, 2024 to August 31, 2026. The project will generate a...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of the neuropeptide S receptor 1 (NPSR1) as a target for reducing opioid self-administration and relapse in opioid use disorder (OUD). The research team at the University of Tennessee Health Science Center plans to leverage pharmacological tools to agonize and antagonize NPSR1 and test...